Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Saneela Tahseen & Shahid Bashir. 2023. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
187
216
.
Mohammad Uzair, Hammad Qaiser, Muhammad Arshad, Aneesa Zafar & Shahid Bashir. 2023. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
147
169
.
Giulia De Feo, Amy A. Case, Gregory B. Crawford, David Hui, Josephine To, Andrea Sbrana, Bryony Alderman, Sandip Mukhopadhyay, Carole Bouleuc, Koji Amano, Kimberson Tanco, Jessica Garsed & Mellar Davis. (2023) Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression. Supportive Care in Cancer 31:3.
Crossref
Adam Stasiulewicz, Anna Lesniak, Magdalena Bujalska-Zadrożny, Tomasz Pawiński & Joanna I. Sulkowska. (2023) Identification of Novel CB2 Ligands through Virtual Screening and In Vitro Evaluation. Journal of Chemical Information and Modeling 63:3, pages 1012-1027.
Crossref
Hina Khan, Fareeha Khalid Ghori, Uzma Ghani, Aneela Javed & Saadia Zahid. (2022) Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis. Molecular Biology Reports 49:6, pages 5117-5131.
Crossref
Johannes G. Ramaekers, Natasha L. Mason, Lilian Kloft & Eef L. Theunissen. (2021) The why behind the high: determinants of neurocognition during acute cannabis exposure. Nature Reviews Neuroscience 22:7, pages 439-454.
Crossref
Jerome Sarris, Justin Sinclair, Diana Karamacoska, Maggie Davidson & Joseph Firth. (2020) Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review. BMC Psychiatry 20:1.
Crossref
Adam Stasiulewicz, Katarzyna Znajdek, Monika Grudzień, Tomasz Pawiński & Joanna I. Sulkowska. (2020) A Guide to Targeting the Endocannabinoid System in Drug Design. International Journal of Molecular Sciences 21:8, pages 2778.
Crossref
Bogdan Ionel Tamba, Gabriela Dumitrita Stanciu, Cristina Mariana Urîtu, Elena Rezus, Raluca Stefanescu, Cosmin Teodor Mihai, Andrei Luca, Gabriela Rusu-Zota, Maria-Magdalena Leon-Constantin, Elena Cojocaru, Bogdan Gafton & Teodora Alexa-Stratulat. (2020) Challenges and Opportunities in Preclinical Research of Synthetic Cannabinoids for Pain Therapy. Medicina 56:1, pages 24.
Crossref
C. S. Constantinescu & P. Gershkovich. (2018) Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited. European Journal of Neurology 25:7, pages 905-906.
Crossref
Petros Georgopoulos, Konstantinos-Vaios Mytilekas & Apostolos Apostolidis. 2018. Neuro-Urology. Neuro-Urology
55
79
.
Melanie E. M. Kelly, Christian Lehmann & Juan Zhou. (2017) The Endocannabinoid System in Local and Systemic Inflammation. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 9:2, pages i-192.
Crossref
Charles D. Ciccone. (2017) Medical Marijuana: Just the Beginning of a Long, Strange Trip?. Physical Therapy 97:2, pages 239-248.
Crossref
. 2014. Cannabinoids. Cannabinoids
i
xx
.
Jessica Robb, Lawrence M. Samkoff & Andrew D. Goodman. 2014. Multiple Sclerosis and CNS Inflammatory Disorders. Multiple Sclerosis and CNS Inflammatory Disorders
102
113
.
Waldemar Brola, Krystyna Mitosek-Szewczyk & Józef Opara. (2014) Symptomatology and pathogenesis of different types of pain in multiple sclerosis. Neurologia i Neurochirurgia Polska 48:4, pages 272-279.
Crossref
Edward A Shipton & Elspeth E Shipton. (2014) Should doctors be allowed to prescribe cannabinoids for pain in Australia and New Zealand?. Australian & New Zealand Journal of Psychiatry 48:4, pages 310-313.
Crossref